Biotechnology - Biotechnology, Genentech

Filter

Current filters:

BiotechnologyGenentech

Popular Filters

1 to 25 of 44 results

Phylogica inks $142 million license deal with Genentech

Phylogica inks $142 million license deal with Genentech

22-12-2014

Australian drug discovery firm Phylogica has extended its collaboration with Genentech, the biotech subsidiary…

Antibiotics and Infectious diseasesAustraliaBiotechnologyGenentechLicensingPhylogicaResearchRoche

Roche shares fall sharply on disappointing Ph III MARIANNE study

Roche shares fall sharply on disappointing Ph III MARIANNE study

22-12-2014

Swiss pharma major Roche saw its shares plunge 6.4% to 270.40 Swiss francs on Friday following release…

BiotechnologyGenentechHerceptinKadcylaOncologyPerjetaRoche

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

15-12-2014

Genentech, the US biotech subsidiary of Swiss Pharma major Roche Group, has submitted a New Drug Application…

BiotechnologycobimetinibExelixisGenentechOncologyRegulationRocheUSAZelboraf

Yet another indication for Roche’s blockbuster Avastin from FDA

16-11-2014

The US Food and Drug Administration on Friday approved Avastin (bevacizumab) solution for intravenous…

AvastinBiotechnologyEli LillyGemzarGenentechOncologyRegulationRocheUSA

NewLink Genetics out-licenses NLG919 to Genentech

NewLink Genetics out-licenses NLG919 to Genentech

20-10-2014

US biotech firm NewLink Genetics saw its share price rocket 21.2% in morning trading today, after it…

BiotechnologyGenentechGlobalLicensingNewLink GeneticsNLG919OncologyRoche

Eylea beats Avastin and Lucentis for visual acuity in DME patients

Eylea beats Avastin and Lucentis for visual acuity in DME patients

19-10-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer saw their shares leap 8.5% to…

AvastinBayerBiotechnologyEyleaGenentechLucentisNovartisOphthalmicsRegeneron PharmaceuticalsResearchRoche

Genentech files sBLA for Lucentis for diabetic retinopathy

09-08-2014

Genentech, the biotech subsidiary of Swiss pharma major Roche, has submitted a supplemental Biologics…

BiotechnologyGenentechLucentisOphthalmicsRegulationRocheUSA

Roche to acquire Seragon in deal that could reach over $1.7 billion

Roche to acquire Seragon in deal that could reach over $1.7 billion

02-07-2014

Swiss drug major Roche says its USA-based biotech subsidiary Genentech has entered into a definitive…

BiotechnologyGenentechMergers & AcquisitionsOncologyRocheSeragon Pharmaceuticals

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

03-03-2014

An independent data monitoring committee has recommended that Swiss drug major Roche’s Phase III METLung…

BiotechnologyGenentechonartuzumabOncologyResearchRoche

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

PDL BioPharma settles litigation with Genentech and Roche

03-02-2014

US drugmaker PDL BioPharma has entered into an agreement with Genentech and its parent, Swiss drug major…

BiotechnologyFinancialGenentechLegalOncologyOphthalmicsPDL BioPharmaRoche

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL

04-11-2013

The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production

14-10-2013

Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

FDA advisory panel backs new indication for Genentech's Perjeta

13-09-2013

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

US Court denies re-hearing of Arzerra patent case

16-07-2013

Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

Conditional EU approval for Roche basal cell carcinoma drug

15-07-2013

The European Commission has granted conditional approval to Swiss drug major Roche's (ROG: SIX) Erivedge…

BiotechnologyCurisErivedgeEuropeGenentechOncologyPharmaceuticalRegulationRoche

Immunocore and Genentech collaborate to develop ImmTACs for multiple cancer targets

01-07-2013

Immunocore, an Oxford, UK-based biotechnology company developing novel biological drugs known as ImmTACs…

BiotechnologyGenentechLicensingOncologyResearchRoche

PDL files for arbitration for alleged royalties underpayments by Genentech

11-06-2013

USA-based PDL BioPharma (Nasdaq: PDLI) revealed today (June 11) that it has filed a Notice of Arbitration…

BiotechnologyFinancialGenentechLegalPDL BioPharmaPharmaceuticalRoche

Roche's Avastin extends lives of cervical cancer patients; positive in glioblastoma

03-06-2013

Data presented from the study, known as GOG240, showed that the addition of Swiss pharma major Roche's…

AvastinBiotechnologyGenentechOncologyPharmaceuticalResearchRoche

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Strong initial data on Genentech's obinutuzumab in most common blood cancer

16-05-2013

Genentech, the biotech subsidiary of Swiss drug major Roche Group (ROG: SIX), has announced positive…

BiotechnologyGA101GenentechobinutuzumabOncologyResearchRoche

US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018

10-04-2013

US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

1 to 25 of 44 results

Back to top